Longitudinal Changes in Epigenetic Age Acceleration in Aviremic Human Immunodeficiency Virus-Infected Recipients of Long-term Antiretroviral Treatment
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com..
BACKGROUND: Human immunodeficiency virus (HIV) infection induces epigenetic age acceleration (EAA), but it remains unclear whether epigenetic aging continues to accelerate during successful antiretroviral therapy (ART) and prolonged virological suppression.
METHODS: We longitudinally analyzed 63 long-term aviremic HIV-infected adults. Using blood DNA methylation patterns, we calculated EAA measures based on 3 epigenetic clocks (Horvath's clock, PhenoAge, and GrimAge). We recorded the emergence of serious AIDS-related and non-AIDS-related events throughout the study to assess its association with EAA.
RESULTS: All participants were on stable ART and were virologically suppressed. After 4 years of follow-up, PhenoAge-EAA and GrimAge-EAA showed no differences, whereas Horvath-EAA slightly decreased (median difference, -0.53 years; P = .015). Longitudinal changes in EAA measures were independent of changes in CD4 cell counts, the ART regimen, or other HIV-related factors. Nineteen percent of participants experienced a serious clinical event during the study. Horvath-EAA was significantly higher at baseline in participants with clinical events (P = .027). After adjusting for confounders, we found a trend toward an association of higher levels of all EAA measures at baseline with serious clinical events.
CONCLUSIONS: Epigenetic aging did not accelerate in long-term aviremic HIV-infected adults after 4 years of successful ART. EAA measures deserve further study as potential tools for predicting clinical events.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:225 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 225(2022), 2 vom: 18. Jan., Seite 287-294 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Esteban-Cantos, Andrés [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aging |
|---|
| Anmerkungen: |
Date Completed 15.02.2022 Date Revised 15.02.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiab338 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327137142 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327137142 | ||
| 003 | DE-627 | ||
| 005 | 20231225200117.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiab338 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM327137142 | ||
| 035 | |a (NLM)34166509 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Esteban-Cantos, Andrés |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Longitudinal Changes in Epigenetic Age Acceleration in Aviremic Human Immunodeficiency Virus-Infected Recipients of Long-term Antiretroviral Treatment |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2022 | ||
| 500 | |a Date Revised 15.02.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Human immunodeficiency virus (HIV) infection induces epigenetic age acceleration (EAA), but it remains unclear whether epigenetic aging continues to accelerate during successful antiretroviral therapy (ART) and prolonged virological suppression | ||
| 520 | |a METHODS: We longitudinally analyzed 63 long-term aviremic HIV-infected adults. Using blood DNA methylation patterns, we calculated EAA measures based on 3 epigenetic clocks (Horvath's clock, PhenoAge, and GrimAge). We recorded the emergence of serious AIDS-related and non-AIDS-related events throughout the study to assess its association with EAA | ||
| 520 | |a RESULTS: All participants were on stable ART and were virologically suppressed. After 4 years of follow-up, PhenoAge-EAA and GrimAge-EAA showed no differences, whereas Horvath-EAA slightly decreased (median difference, -0.53 years; P = .015). Longitudinal changes in EAA measures were independent of changes in CD4 cell counts, the ART regimen, or other HIV-related factors. Nineteen percent of participants experienced a serious clinical event during the study. Horvath-EAA was significantly higher at baseline in participants with clinical events (P = .027). After adjusting for confounders, we found a trend toward an association of higher levels of all EAA measures at baseline with serious clinical events | ||
| 520 | |a CONCLUSIONS: Epigenetic aging did not accelerate in long-term aviremic HIV-infected adults after 4 years of successful ART. EAA measures deserve further study as potential tools for predicting clinical events | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HIV infection | |
| 650 | 4 | |a aging | |
| 650 | 4 | |a antiretroviral therapy | |
| 650 | 4 | |a epigenetic age acceleration | |
| 650 | 7 | |a Anti-Retroviral Agents |2 NLM | |
| 700 | 1 | |a Montejano, Rocio |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Centeno, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Saiz-Medrano, Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a De Miguel, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Barruz, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardino, Jose I |e verfasserin |4 aut | |
| 700 | 1 | |a Mena-Garay, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Cadiñanos, Julen |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez-González, María |e verfasserin |4 aut | |
| 700 | 1 | |a Nevado, Julián |e verfasserin |4 aut | |
| 700 | 1 | |a Valencia, Eulalia |e verfasserin |4 aut | |
| 700 | 1 | |a Mayoral-Muñoz, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Arribas, Jose R |e verfasserin |4 aut | |
| 700 | 1 | |a Rodés, Berta |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 225(2022), 2 vom: 18. Jan., Seite 287-294 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:225 |g year:2022 |g number:2 |g day:18 |g month:01 |g pages:287-294 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiab338 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 225 |j 2022 |e 2 |b 18 |c 01 |h 287-294 | ||